Antibody Expression Vectors for Transcript Ratio Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of recombinant antibodies remains a complex and expensive process, necessitating improved methods for enhancing the quantity and quality of antibody production.
Innovation Solution
The use of specific configurations of antibody-encoding genes in protein expression vectors, where the order and positioning of genes within the vectors, along with recombinase-mediated integration, optimize transcription and yield of antibodies in mammalian host cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional expression vectors are used for antibody production, then the production process is simpler, but the quantity and quality of recombinant antibodies generated is insufficient
Solution Approach 1:
The patent divides the antibody expression system into separate modular components: a first expression vector containing the light chain gene and a second expression vector containing the heavy chain gene. Each vector can be independently designed, optimized, and manipulated, allowing for systematic improvement of antibody production without overwhelming complexity
Solution Approach 2:
The patent applies different configurations and optimization strategies to different parts of the expression system. The light chain and heavy chain vectors have distinct structural arrangements, promoter elements, and regulatory sequences tailored to their specific requirements, enabling localized optimization that collectively enhances overall antibody productivity
2Manufacturing precision
If conventional expression vectors are used for antibody production, then the vector design is simpler, but the heavy to light chain transcript ratio is suboptimal
Solution Approach 1:
The patent implements asymmetric configurations in the two expression vectors with different promoter strengths, enhancer elements, and regulatory sequences specifically tailored to achieve the desired heavy-to-light chain transcript ratio. The heavy chain vector contains stronger transcriptional activation elements compared to the light chain vector, precisely controlling the stoichiometry of antibody assembly
Solution Approach 2:
The patent systematically varies critical transcriptional parameters including promoter sequence composition, enhancer placement, 5' UTR length, and 3' UTR elements in the expression vectors to optimize the heavy-to-light chain transcript ratio, achieving precise control over antibody production stoichiometry
3Productivity
If complex expression systems are used to improve antibody yield, then antibody productivity increases, but the production process becomes more expensive
Solution Approach 1:
By segmenting the expression system into two separate vectors with specialized functions, the patent enables independent optimization and troubleshooting of each component, reducing overall process complexity and cost while maintaining high productivity. This modular approach allows for more efficient manufacturing compared to complex single-vector systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach leads to improved transcription levels and antibody product yield, specifically increasing the heavy to light chain transcript ratio, resulting in enhanced antibody productivity and quality.
Implementation Method 1
the first recombination sequence of the first exogenous nucleic acid construct and the first recombination sequence of the second exogenous nucleic acid construct are recognized by the same recombinase enzyme
Data Source
AI summary
Vectors and nucleic acid constructs for improved antibody production are provided. Also provided are methods of making and using the vectors and constructs.